1227O Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors
Janjigian Y, Smit E, Horn L, Groen H, Camidge D, Gettinger S, Fu Y, Denis L, Miller V, Pao W. 1227O Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors. Annals Of Oncology 2012, 23: ix400-ix401. DOI: 10.1016/s0923-7534(20)33838-2.Peer-Reviewed Original ResearchProgression-free survivalTyrosine kinase inhibitorsBoehringer IngelheimObjective responseClinical dataProbability of PFSMutant non-small cell lung cancerEGFR-mutant non-small cell lung cancerNon-small cell lung cancerMedian progression-free survivalEGFR T790M mutationClovis OncologyEGFR T790M testingErbB family blockerCell lung cancerEarly clinical dataCombination of afatinibEGFR-mutant NSCLCSpecific tyrosine kinase inhibitorT790M mutationUniversity Medical CenterTransgenic murine modelT790M testingEpidermal growth factor receptorEligible pts